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Abstract 
 
CB1 cannabinoid receptor (CB1R) undergoes both constitutive and agonist-induced 
internalization, but the underlying mechanisms of these processes and the role of β-
arrestins in the regulation of CB1R function are not completely understood. In this study, 
we followed CB1R internalization using confocal microscopy and bioluminescence 
resonance energy transfer measurements in HeLa and Neuro-2a cells. We found that upon 
activation CB1R binds β-arrestin2 (β-arr2), but not β-arrestin1. Furthermore, both the 
expression of dominant-negative β-arr2 (β-arr2-V54D) and siRNA-mediated knock-down 
of β-arr2 impaired the agonist-induced internalization of CB1R.  In contrast, neither β-
arr2-V54D nor β-arr2-specific siRNA had a significant effect on the constitutive 
internalization of CB1R. However, both constitutive and agonist-induced internalization 
of CB1R were impaired by siRNA-mediated depletion of clathrin heavy chain. We 
conclude that although clathrin is required for both constitutive and agonist-stimulated 
internalization of CB1R, β-arr2 binding is only required for agonist-induced 
internalization of the receptor suggesting that the molecular mechanisms underlying 
constitutive and agonist-induced internalization of CB1R are different. 
 
Keywords: β-arrestin, bioluminescence resonance energy transfer (BRET), CB1 
cannabinoid receptor, constitutive internalisation, G protein-coupled receptors (GPCR), 
receptor endocytosis 
 
1. Introduction 
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Internalization of G protein-coupled receptors (GPCRs) is an important process in 
the regulation of receptor function. Although its main function is the modulation of 
receptor number on the cell surface, thereby adjusting the sensitivity of the cell to 
external stimuli, it also plays role in the resensitization and signaling of GPCRs 
(Ferguson, 2001; Hunyady and Catt, 2006; Shenoy and Lefkowitz, 2011). At the 
molecular level, β-arrestins are key regulatory proteins of receptor internalization, as they 
can bind to activated GPCRs, as well as to clathrin and the adaptor protein AP-2, thus 
directing the receptor towards clathrin-mediated endocytosis (Shenoy and Lefkowitz, 
2011). β-arrestins also mediate receptor desensitization, as their binding to the activated 
GPCRs causes the uncoupling of the receptor from its cognate G protein (Shenoy and 
Lefkowitz, 2011). Furthermore, they play important roles in the activation of G protein-
independent signal transduction pathways, e.g. the activation of MAP kinases, 
phosphatidylinositol 3 kinase, Akt or the small GTP-ase RhoA (DeWire et al., 2007; Wei 
et al., 2003). 
β-arrestin1 (β-arr1) and β-arrestin2 (β-arr2) are two ubiquitously expressed 
isoforms of β-arrestins (Ferguson, 2001). Although β-arrestin binding is a general 
property of most activated GPCRs, the selectivity and stability of these binding shows 
receptor specific differences. Namely, class A receptors (e.g. the β2 adrenergic receptor) 
bind β-arr2 with a higher affinity than β-arr1, and this binding is transient, i.e. it can only 
be detected at or near the plasma membrane. In contrast, class B GPCRs, such as the AT1 
angiotensin receptor, bind both β-arr1 and β-arr2 with relatively high affinity and form 
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stable complexes with β-arrestins, so that β-arrestins remain bound to the receptor after 
internalization and can be detected on intracellular vesicles (Oakley et al., 2000). 
The CB1 cannabinoid receptor (CB1R) belongs to the superfamily of G protein-
coupled receptors (GPCRs). The receptor plays role in many important physiological 
processes, such as learning, thinking, nociception or the regulation of food-intake (Pacher 
et al., 2006). Activation of presynaptic CB1Rs by postsynaptic endocannabinoid release, 
which mediates retrograde transmission, is a key regulatory mechanism in the central 
nervous system, but paracrine activation of CB1Rs with a similar mechanism can also 
occur in extraneural tissues (Freund et al., 2003; Gyombolai et al., 2012; Sanchez et al., 
2001; Turu et al., 2009; Szekeres et al., 2012). The cellular signaling events following 
CB1R activation are mainly associated with the activation of heterotrimeric Gi/o-proteins 
and include inhibition of adenylyl cyclases, activation of Kir channels, inhibition of Cav 
channels and phosphorylation and activation of different subtypes of mitogen-activated 
protein kinases (MAP kinases) (Turu and Hunyady, 2010). G protein-independent 
signaling events following CB1R stimulation have also been reported (Sanchez et al., 
2001).  
Similar to most GPCRs, CB1R internalizes upon agonist stimulation. This has 
been demonstrated in many cell lines, including CHO (Rinaldi-Carmona et al., 1998), 
AtT20 (Hsieh et al., 1999; Jin et al., 1999; Roche et al., 1999), F11 (Coutts et al., 2001), 
neuroblastoma N18TG2 (Keren and Sarne, 2003) and HEK293 (Keren and Sarne, 2003; 
Leterrier et al., 2004) cells, as well as in hippocampal neurons, which naturally express 
CB1R (Coutts et al., 2001; Leterrier et al., 2006). According to different studies, this 
agonist-induced CB1R endocytosis occurs via clathrin- and/or caveolin-mediated 
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pathways in different cell types (Bari et al., 2008; Hsieh et al., 1999; Keren and Sarne, 
2003; Wu et al., 2008). 
Numerous studies suggest that β-arr2 is involved in the regulation of CB1R. Co-
expression of both GRK3 and β-arr2 was needed for the proper desensitization of the 
receptor in Xenopus oocyte (Jin et al., 1999), and dominant negative GRK2 and β-
arrestin constructs reduced CB1R desensitization in hippocampal neurons (Kouznetsova 
et al., 2002). In β-arr2 knockout mice desensitization and downregulation of CB1R were 
impaired in certain regions of the central nervous system (Nguyen et al., 2012). 
Recruitment of β-arr2 to the activated CB1R has also been demonstrated (Daigle et al., 
2008a). Mutation of amino acids S426 and S430 was shown to inhibit receptor 
desensitization as well as late phase receptor endocytosis, but not β-arrestin binding 
(Daigle et al., 2008b; Jin et al., 1999). It has been demonstrated that serine and threonine 
residues at the C-terminus of CB1R are involved in its β-arr2 binding and agonist-induced 
endocytosis (Daigle et al., 2008b; Hsieh et al., 1999). In contrast to the various studies 
that clearly point to an interaction between CB1R and β-arr2 upon agonist stimulation, no 
direct data have been hitherto presented concerning the β-arr1 binding of CB1R. In some 
structural studies, the association of β-arr1 with a synthesized CB1R C-terminus has been 
shown (Bakshi et al., 2007; Singh et al., 2011), however, such binding has not been 
demonstrated with the intact CB1R in living cells.  
Constitutive internalization of CB1R (i.e. spontaneous internalization in the 
absence of CB1R agonists) has also been detected in hippocampal neurons, as well as in 
CHO and HEK cells (Leterrier et al., 2004, 2006; McDonald et al., 2007a; Turu et al., 
2007). It has been suggested that constitutive CB1R internalization is the consequence of 
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its basal activity, since inverse agonist treatment or inhibition of basal activity with a 
DAG lipase inhibitor (e.g. tetrahydrolipstatin) interfered with this process (Leterrier et al., 
2004, 2006; Rinaldi-Carmona et al., 1998; Turu et al., 2007). However, other studies 
have concluded that constitutive internalization occurs independently of receptor activity 
(McDonald et al., 2007a, 2007b; Kleyer et al., 2012). The latter statement raises the 
possibility that constitutive and agonist-induced internalization of CB1R may occur via 
distinct endocytic mechanisms (McDonald et al., 2007a). However, no evidence has been 
hitherto presented showing that these two processes are truly different in that they require 
distinct endocytic machinery to take place. 
Our main goal was, considering the important consequences of β-arrestin 
recruitment in the regulation of cell function, to characterize the β-arrestin binding 
properties of CB1R and to reveal possible differences in constitutive and agonist-driven 
CB1R endocytosis by investigating the role of β-arrestins in these processes. 
 
2. Materials and Methods 
 
2.1. Materials  
The cDNAs of the rat vascular CB1R and CB1R-eYFP were provided by Zsolt Lenkei 
(Centre National de la Recherche Scientificue, Paris). β-arrestin1, β-arrestin2 and β-
arrestin2-eGFP cDNAs were kindly provided by Dr. Marc G. Caron (Duke University, 
Durham, NC). Molecular biology enzymes were obtained from Fermentas (Vilnius, 
Lithuania) and Stratagene (La Jolla, CA). pcDNA3.1 vector, coelenterazine h, fetal 
bovine serum (FBS), OptiMEM, Lipofectamine 2000, and PBS-EDTA were from 
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Invitrogen (Carlsbad, CA). WIN55,212-2 and AM251 were from Tocris (Bristol, UK). 
Cell culture dishes and plates for BRET measurements were from Greiner 
(Kremsmunster, Austria). HaloTag® Alexa Fluor® 488 Ligand was from Promega 
(Madison, WI). Control siRNA, human β-arrestin2-specific siRNA, mouse β-arrestin2-
specific siRNA and clathrin heavy chain-specific siRNA (with sequences 5’-
UUCUCCGAACGUGUCACGU-3’, 5’-GGACCGCAAAGUGUUUGUG-3’, 5’- 
ACGUCCAUGUCACCAACAA-3’ and 5’-GAAAGAAUCUGUAGAGAAA-3’, 
respectively) were from Eurofins MWG Operon (Ebersberg, Germany). HeLa and Neuro-
2a cells were from ATCC (American Type Culture Collection, Manassas, VA). Anti-β-
arrestin2 and HRP-conjugated anti-rabbit and anti-mouse antibodies were from Cell 
Signaling Technology Inc. (Beverly, MA). Anti-clathrin heavy chain antibody was from 
Transduction Laboratories (Lexington, KY). Unless otherwise stated, all other chemicals 
and reagents were from Sigma (St. Louis, MO). 
 
2.2. Plasmid constructs and site-directed mutagenesis 
The mVenus-tagged rat AT1a receptor (AT1R-mVenus), human β2 adrenergic receptor 
(β2AR-mVenus) and rat CB1R (CB1R-mVenus) were created by exchanging the sequence 
of fluorescent proteins in AT1R-YFP (Turu et al., 2006), β2AR-Sluc (Toth et al., 2012) or 
CB1R-YFP, respectively, to the sequence of mVenus using AgeI and NotI restriction 
enzymes. The mCherry-tagged AT1R (AT1R-mCherry) and Cerulean-tagged β2AR 
(β2AR-Cerulean) were created similarly. β-arrestin2-Rluc was constructed as described 
previously (Turu et al., 2006). β-arrestin1-Rluc and β-arrestin1-GFP were generated from 
β-arrestin2-Rluc and β-arrestin2-GFP, respectively, by replacing the cDNA of β-arrestin2 
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with that of β-arrestin1. CB1R-mCherry and β-arrestin2-RFP were constructed by 
subcloning the cDNAs of CB1R or β-arrestin2 into mCherry or RFP containing vectors 
(provided by Dr.R. Tsien, University of California, San Diego, CA), respectively. For the 
construction of Halo-CB1R, the cDNA of HaloTag was first amplified from the 
HaloTag® pHT2 vector (Promega, Madison, WI) by PCR with the sense primer 
containing a cleavable signal sequence of influenza hemagglutinin 
(MKTIIALSYIFCLVFA) to achieve proper plasma membrane localization of the final 
construct (Guan et al., 1992). This product was inserted into a pEGFP-C1 vector 
(Clontech, Palo Alto, CA) in the place of eGFP sequence (pHalo-C1 vector). CB1R 
cDNA was then inserted into pHalo-C1 after the HaloTag cDNA to yield Halo-CB1R. 
CB1R-Sluc was generated from CB1R-YFP by replacing the eYFP coding sequence with 
the cDNA of super Renilla luciferase (Woo and von Arnim, 2008). EYFP-tagged ICAM-
1 (ICAM-YFP) was constructed as described previously (Varnai and Balla, 2007). V54D 
mutation was inserted into the appropriate β-arrestin2 constructs by the QuikChange® 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer’s 
suggestions. Sequences of all constructs were verified using automated DNA sequencing.  
 
2.3. Cell cultures and transfection 
HeLa and Neuro-2a cells were maintained in DMEM supplemented with 10% FBS, 
(Invitrogen, Carlsbad, CA), 100 μg/ml streptomycin, and 100 IU/ml penicillin in 5% CO2 
at 37 °C. For confocal microscopy experiments, HeLa and Neuro-2a cells were grown on 
glass coverslips (coated with poly-L-lysine in the case of Neuro-2a cells) in 6-well plates 
and transfected with the indicated constructs using 1 μg/well of receptor constructs, 0.5 
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μg/well of β-arrestin constructs (as indicated) and/or 25 pmol/well of siRNA (as 
indicated), with 2 μl/well Lipofectamine 2000 in OptiMEM following the manufacturer’s 
instructions. 
For BRET time course experiments, HeLa cells were grown on 6-well plates and 
transfected with the indicated constructs using 1 μg/well of CB1R constructs, 0.5 μg/well 
of β-arrestin constructs, 3 μg/well of ICAM-YFP and/or 25 pmol/well of siRNA (as 
indicated), with 2 μl/well Lipofectamine 2000 in OptiMEM following the manufacturer’s 
instructions. In the case of BRET titration experiments, HeLa cells were transfected with 
constant amounts of donor (β-arr1-Rluc or β-arr2-Rluc) and varying amounts of acceptor 
(CB1R-mVenus,  β2AR-mVenus or AT1R-mVenus) constructs with 2 μl/well 
Lipofectamine 2000 in OptiMEM following the manufacturer’s instructions. The amount 
of total transfected DNA was held constant (2.5 μg/well) with addition of varying 
amounts of empty pcDNA3.1 plasmid. 
 
2.4. Bioluminescence resonance energy transfer (BRET) measurements 
The BRET assay measuring the effects of different CB1R variants on G protein activation 
was carried out as described previously (Turu et al., 2007). To measure BRET between β-
arrestins and receptors, HeLa cells were transfected with Renilla luciferase-tagged β-
arrestin isoforms (β-arr1-Rluc or β-arr2-Rluc) and mVenus-tagged AT1R, β2AR or CB1R, 
and measurements were performed on the day after transfection. To measure BRET 
between ICAM and CB1R, HeLa cells were transfected with eYFP-tagged ICAM-1, super 
Renilla luciferase-tagged CB1R and the indicated β-arr2 construct or siRNA, and 
measurements were performed two days after transfection. Before the experiments cells 
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were detached with PBS-EDTA and centrifuged. Cells were resuspended in a modified 
Krebs-Ringer buffer containing 120 mM NaCl, 4.7 mM KCl, 1.2 mM CaCl2, 0.7 mM 
MgSO4, 10 mM glucose, 0.1% BSA and Na-HEPES 10 mM, pH 7.4; and transferred to 
white 96-well plates. Measurements were performed at 37 °C, after the addition of the 
cell permeable substrate, coelenterazine h at a final concentration of 5 μM. Counts were 
recorded using a Mithras LB 940 multilabel reader (Berthold Technologies, Bad 
Wildbad, Germany) with filters at 485 (for Rluc) and 530 nm (for eYFP) wavelengths. 
BRET ratios were calculated as a 530 nm/485 nm emission ratio. In the case of BRET 
titration experiments, mVenus/Rluc emission ratios were calculated by dividing average 
mVenus fluorescence counts (measured before the addition of coelenterazine h, with 485 
nm excitation and 530 nm emission) by average Rluc bioluminescence counts (measured 
in non-stimulated cells after the addition of coelenterazine h). This was plotted against 
the average BRET ratio change measured 3 to 5 min after agonist stimulus. The 
measurements were done in triplicates, and the BRET records shown here are calculated 
from at least three independent experiments. BRET change was defined as the BRET 
ratio of a given time point minus the average BRET ratio of the initial (non-stimulated) 
time points. BRET change was baseline-corrected to the vehicle curve. 
 
2.5. Confocal laser-scanning microscopy 
Cells were grown on glass coverslips and transfected with the indicated constructs, as 
described above, 48 hours prior to measurement. EGFP (or Halo-Alexa488) and mCherry 
(or RFP) were excited with 488 nm argon, and 543 nm helium/neon lasers, respectively, 
and emitted fluorescence was detected with 500-550 bandpass and 560 longpass filters, 
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respectively, using a Zeiss LSM 510 confocal laser scanning microscope. For 
quantification of confocal measurements, 20 images of individual cells were taken from 
each sample, and intracellular and total cell fluorescence intensities of the images were 
determined using the ImageJ software (W. S. Rasband, ImageJ, United States National 
Institutes of Health, Bethesda, MD (rsb.info.nih.gov/ij/)). Intracellular fluorescence was 
divided by total cell fluorescence to yield IC/total cell fluorescence ratio. Blind selection 
and analysis of the cells were performed to avoid any bias during the evaluation of the 
internalization data. 
 
2.6. Halo-labeling protocols 
To measure agonist-induced internalization of the receptor, Halo-CB1R-transfected cells 
were stained with Halo-Alexa488 ligand diluted 1:20 000 in DMEM, and incubated at 
37°C, 5% CO2 for 15 minutes. Cells were then washed twice with DMEM to remove 
unbound Halo-Alexa488, and treated with DMSO, WIN55,212-2 (10 μM) or 
WIN55,212-2+AM251 (10 μM+30 μM, respectively) at 37°C, 5% CO2 for 30 minutes. 
At the end of stimulation period, cells were washed twice with PBS and fixed with 4% 
formaldehyde at 4°C for 15 minutes. Fixed cells were analyzed under confocal 
microscope as described above. 
To measure constitutive internalization of the receptor, Halo-CB1R-transfected 
cells were stained with Halo-Alexa488 ligand diluted 1:20 000 in DMEM, and incubated 
at 37°C, 5% CO2 for 15 minutes. Cells were then washed twice with DMEM to remove 
unbound Halo-Alexa488 and incubated in DMEM at 37°C, 5% CO2 for 5 hours and 45 
minutes without any further treatment or in the presence of DMSO, WIN55,212-2 (10 
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μM) or AM251 (30 μM). To control the effectiveness of siRNA transfection during the 6 
hours of incubation, parallel samples were subjected to the same washing procedures, 
however, without the staining period at the beginning. For these cells, an ‘agonist-
induced’ protocol (15 min staining + 30 min WIN55 stimulus, see above) was applied 45 
minutes before the end of the experiment. At the end of the 6 hours, all cells were washed 
twice with PBS and fixed with 4% formaldehyde for 15 minutes at 4°C. Fixed cells were 
analyzed under confocal microscope as described above.  
 
2.7. Western blot analysis 
Cells for Western blot analysis were transfected on 6-well plates parallel to the cells 
transfected for confocal analysis. On the day of experiment, cells were placed on ice and 
washed with ice-cold PBS. Cells were scraped into SDS sample buffer, briefly sonicated, 
boiled at 95°C for 5 min, centrifuged at 4°C for 10 min and separated on SDS 
polyacrilamide gels. The proteins were transferred to PVDF membranes, blocked (30 
min, 5% fat-free milk powder in PBS with 0.05% Tween 20 (PBST)) and incubated with 
rabbit anti-β-arrestin2 primary antibody or mouse anti-clathrin heavy chain primary 
antibody (1 h, diluted 1:1000 or 1:4000, respectively, in PBST containing 5% fat-free 
milk powder) and HRP-linked goat anti-rabbit or anti-mouse (respectively) secondary 
antibody (30 min, diluted 1:2000 in PBST containing 5% fat-free milk powder). To 
control the total protein amount of cell samples, antibodies were removed with standard 
stripping buffer and a second immunostaining procedure was carried out with mouse anti-
β-actin primary antibody (1 h, 1:10 000) and HRP-linked goat anti-mouse secondary 
antibody (30 min, 1:10 000). The antibodies were visualized using SuperSignal West 
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Pico reagent (Pierce Biotechnology Inc., Rockford, IL), according to manufacturer’s 
instructions. Western blot images were scanned and quantified using the ImageJ software. 
Changes in β-actin levels were used to normalize changes in β-arr2 or clathrin heavy 
chain levels. 
 
2.8. Statistical analysis 
Statistical analysis was made using the software SigmaStat for Windows 3.5 (Systat 
Software Inc., Richmond, CA). The effects of co-transfected siRNAs were evaluated 
using Student’s t-test or two-way ANOVA with Holm-Sidak’s post-hoc test, as 
appropriate. Data shown are mean ± SEM values. 
 
3. Results 
 
3.1. β-arrestin binding properties of CB1R 
β-arrestin binding properties of CB1R were first analyzed using a bioluminescence 
resonance energy transfer (BRET) based approach. BRET was measured between Renilla 
luciferase tagged β-arr1 or β-arr2 (β-arr1-Rluc and β-arr2-Rluc) and the mVenus-tagged 
CB1R (CB1R-mVenus) in transiently transfected HeLa cells. Stimulation using 
WIN55,212-2 (WIN55, 10 μM), a potent synthetic CB1R agonist, led to an increase in the 
BRET signal when β-arr2-Rluc was co-expressed with CB1R-mVenus (Fig. 1A) 
reflecting the recruitment of the β-arr2-Rluc molecules to CB1R-mVenus following 
receptor activation. In contrast, the same stimulus did not cause any detectable change in 
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the BRET signal between β-arr1-Rluc and CB1R-mVenus (Fig. 1A), indicating that this 
subtype of β-arrestin does not bind to CB1R following receptor activation.  
To investigate the β-arrestin binding of CB1R more thoroughly, BRET titration 
experiments were performed. In these experiments, BRET signal is measured and plotted 
as a function of the BRET acceptor/donor (mVenus/Rluc) expression ratio. In case of a 
specific interaction, such as the binding between a GPCR and β-arrestins upon agonist 
stimulus, BRET titration follows a saturation curve, the slope of which corresponds to the 
affinity between the two BRET partners (Marullo and Bouvier, 2007). Thus, BRET 
titration experiments were carried out between CB1R-mVenus and β-arr1-Rluc or β-arr2-
Rluc. Furthermore, the mVenus-tagged β2-adrenoceptor and  AT1 angiotensin receptor 
(β2AR-mVenus and AT1R-mVenus, respectively) were also tested for their β-arrestin 
affinities in the same system, as these two receptors are prototypical class A and class B 
GPCRs, respectively (Oakley et al., 2000), and therefore their β-arrestin binding 
properties could be used as a reference in our experiments. As expected, BRET titration 
curves of β2AR-mVenus and AT1R-mVenus followed saturation kinetics with both β-
arrestin isoforms after agonist stimulus. While AT1R-mVenus binds both isoforms with 
high affinity (Fig. 1B), in case of β2AR-mVenus, substantial difference was observed 
between β-arr1-Rluc and β-arr2-Rluc binding, showing that this GPCR has substantially 
higher affinity for β-arr2 (class A GPCR, Fig. 1C). BRET titration curve of CB1R-
mVenus and β-arr2-Rluc also followed saturation kinetics, however, with a very low 
steepness. In contrast, no detectable BRET signal change occurred with β-arr1-Rluc even 
at high acceptor/donor ratios (Fig. 1D).  
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β-arrestin binding of CB1R was also visualized using confocal microscopy. In 
HeLa cells transiently transfected with mCherry-tagged CB1R (CB1R-mCherry) and 
GFP-tagged β-arr1 or  β-arr2 (β-arr1-GFP or β-arr2-GFP, respectively), CB1R-mCherry 
was present at the plasma membrane as well as in intracellular vesicles in non-stimulated 
cells. This distribution corresponds to constitutive internalization of CB1R, a well-known 
property of this receptor (Fig. 2B and F). On the other hand, both  β-arr1-GFP and β-arr2-
GFP showed diffuse cytoplasmic (and, in the case of β-arr1-GFP, also nuclear) 
localization in non-stimulated cells, without any detectable β-arrestin either at the plasma 
membrane or in intracellular vesicles (Fig. 2A and E). After stimulation with WIN55, 
marked redistribution of β-arr2-GFP could be observed within a few minutes, namely it 
appeared in punctuate structures at the plasma membrane. However, the inner regions of 
the cytoplasm showed no accumulation of β-arr2-GFP containing vesicles even after 
longer periods of stimulation (Fig. 2G). In contrast to β-arr2-GFP, β-arr1-GFP showed no 
change in its localization after WIN55 stimulus (Fig. 2C), indicating that this subtype of 
β-arrestin does not bind to CB1R. In the same system, fluorescently labeled β2AR and 
AT1R showed β-arrestin binding pattern, which are in good agreement with their class A 
and class B behavior, respectively, i.e. β2AR bound β-arr1 and β-arr2 only at the plasma 
membrane (Suppl. Fig. 1A-D), whereas AT1R remained bound with both isoforms in 
endosomal vesicles (Suppl. Fig. 1E-H). 
The above data indicate that, based on its β-arrestin binding properties, CB1R 
belongs to the class A group of GPCRs, i.e. upon activation, β-arr2 binds to the receptor, 
but remains bound to it only in the proximity of the plasma membrane, whereas CB1R 
does not recruit β-arr1. 
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3.2. Dominant-negative β-arr2 impairs agonist-induced CB1R internalization 
Next, the agonist-induced internalization of CB1R was investigated. We utilized the Halo 
labeling technique, as the analysis of the internalization of C-terminally tagged CB1R 
variants using confocal microscopy is difficult because of the presence of the 
constitutively internalized intracellular receptor population. The HaloTag protein was 
fused to the N-terminus of the receptor (Halo-CB1R). When expressed by the cells, 
HaloTag is able to rapidly and covalently bind Halo-Alexa488, its membrane-impermeant 
fluorescent ligand. Using this method, the receptor population residing in the plasma 
membrane can be selectively stained, and their internalization can be followed. The 
functionality of Halo-CB1R was tested using BRET assays measuring the G protein 
activation and the β-arr2 binding of the receptors upon WIN55 stimulus, and no 
significant difference was detected between the EC50 (mol/l) values of wild-type and 
HaloTag-labeled CB1R dose-response curves (pEC50 8.98±0.22 versus 9.02±0.12 for G 
protein activation and 6.48±0.14 versus 6.49±0.08 for β-arr2 binding, respectively, n=3). 
To study agonist-induced internalization, cells were stained for 15 minutes, treated with 
vehicle or CB1R ligand for 30 minutes, and then fixed and analyzed using confocal 
microscopy. In vehicle-treated cells, plasma membrane staining was clearly detectable, 
and labeling of intracellular vesicles was minimal (Fig. 3A). WIN55 treatment resulted in 
the appearance of numerous intracellular vesicles, representing intensive agonist-induced 
internalization, which was inhibited by the CB1R inverse agonist AM251 (Fig. 3B-C). To 
study the role of β-arr2 in this process, first, a dominant-negative β-arr2 mutant, β-arr2-
V54D (β-arr2-V54D) was applied. This mutant has reduced ability to bind to GPCRs 
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(Ferguson et al., 1996; Krupnick et al., 1997), and has been widely used to study the role 
of β-arr2 in receptor internalization. We co-expressed the RFP-tagged form of wild-type 
or V54D mutant β-arr2 (β-arr2-RFP and β-arr2-V54D-RFP, respectively) with Halo-
CB1R. Co-expression of β-arr2-RFP did not impair the WIN55-induced CB1R 
internalization (Fig. 3D-G). However, in cells expressing β-arr2-V54D-RFP, agonist-
induced internalization of Halo-CB1R was markedly reduced (Fig. 3H-K), suggesting a 
role for β-arr2 in agonist-induced CB1R internalization. 
 
3.3.  siRNA-mediated knock-down of β-arr2 impairs agonist-induced internalization of 
CB1R 
siRNA-mediated knock-down of a protein provides an alternative approach to study its 
role in a given mechanism. Therefore, the effects of transfection of cells with β-arr2-
specific siRNA (β-arr2 siRNA) were also investigated. Western blot analysis showed 
approximately 50% reduction in β-arr2 protein levels of these cells (Fig. 4A). 
Internalization of Halo-CB1R in these experiments was analyzed as described above. 
CB1R internalization upon WIN55 treatment was intact in cells transfected with control 
siRNA, but was markedly reduced in β-arr2 siRNA-transfected cells (Fig. 4B-E). As the 
cells that were transfected with siRNA could not be individually identified in these 
experiments, quantification of the samples was carried out to properly evaluate the effects 
of siRNA transfection. This showed a significant inhibitory effect of β-arr2 siRNA on 
agonist-induced CB1R internalization (Fig. 4F).  
 
3.4. Agonist-induced internalization of CB1R 
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To investigate the agonist-induced internalization of CB1R in a more quantitative way, 
we monitored the movement of the receptor between the plasma membrane and the 
cytoplasm, by measuring BRET between the YFP-tagged form of ICAM-1, a plasma 
membrane resident protein (ICAM-YFP), and the SuperRenilla luciferase-tagged CB1R 
(CB1R-Sluc) in transiently transfected HeLa cells. In cells expressing CB1R-Sluc and 
ICAM-YFP, WIN55 stimulus led to a decrease in the BRET signal, indicating the 
removal of CB1R-Sluc from the plasma membrane (Fig. 5A). This decrease reached its 
maximum 10 to 20 minutes after stimulation, and showed then no considerable change 
until the end of the measurement (at approximately 40 minutes after stimulation). 
Overexpression of wild-type β-arr2 had no significant effect on CB1R internalization. 
However, when β-arr2-V54D was co-expressed in the cells, the extent of the BRET-
decrease upon WIN55 stimulus was significantly lower than that observed in control cells 
(Fig. 5A). The effect of siRNA mediated β-arr2 knock-down on CB1R internalization was 
also studied using the same BRET assay. We found that the knock-down of β-arr2 with β-
arr2 siRNA resulted in a marked reduction of BRET signal decrease after CB1R 
activation, reflecting the impaired agonist-induced internalization of the receptor (Fig. 
5B).  
These data indicate that β-arr2 binding is required for the agonist-induced 
internalization of CB1R, since interference with this binding following receptor 
activation, either caused by dominant-negative effect or through the genetic knock-down 
of β-arr2, results in impairment of agonist-induced CB1R internalization. 
 
3.5. Constitutive CB1R internalization is not affected by β-arr2 impairment 
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Recent data suggest that constitutive internalization may occur independently of CB1R 
activity (McDonald et al., 2007a, 2007b; Kleyer et al., 2012), and since β-arr2 coupling is 
an activity-dependent process, it raises the possibility that it is a second, differently 
regulated endocytic process. Therefore we monitored receptor constitutive endocytosis 
using similar approaches with Halo-tagged CB1R to address possible differences in its 
regulation compared to agonist-induced internalization.  In these experiments, cells were 
stained for 15 minutes with the Alexa488-conjugated Halo-ligand, and incubated for a 
total of 6 hours in medium to allow spontaneous CB1R endocytosis to occur. In control 
cells, a large number of vesicles could be seen intracellularly, demonstrating constitutive 
endocytosis of CB1R (Fig. 6A). This could be further enhanced with WIN55 treatment, 
whereby hardly any detectable receptor was present on the plasma membrane by the end 
of the 6 hours incubation period (Fig. 6B). AM251 treatment along the 6 hours had no 
inhibitory effect on constitutive CB1R internalization (Fig. 6C), showing that this form of 
internalization is not dependent on receptor activity. When studying the role of β-arr2 in 
this process, cells co-expressing β-arr2-RFP showed no detectable change in the extent of 
constitutive internalization (Fig. 6D-E). Moreover, in contrast to agonist-induced 
endocytosis, in cells co-expressing the dominant-negative mutant β-arr2 (β-arr2-V54D-
RFP), intracellular Halo-CB1R-containing vesicles were still present, in a similar extent 
as in control or β-arr2-RFP expressing cells (Fig. 6F-G). When cells were co-transfected 
with either control or β-arr2 siRNA, no significant difference in the intracellular vs. total 
cell fluorescence ratio could be detected between these cells after 6 hours of incubation, 
showing that constitutive internalization of CB1R was not affected (Fig. 7A). The effect 
of siRNA was not attenuated throughout the incubation period, as in the same 
  20 
experiments, agonist-induced CB1R internalization was still impaired when tested at the 
end of the incubation period (Fig. 7B). These data suggest that β-arr2 is not required for 
the spontaneous internalization of CB1R. Similar results were obtained when Halo-CB1R 
internalization was investigated in a Neuro-2a mouse neuroblastoma cell line, which is 
known to endogenously express CB1R (Graham et al., 2006). siRNA mediated knock-
down of β-arr2 (resulting in an approximately 80% reduction of β-arr2 protein levels, 
Suppl. Fig. 1A) impaired agonist-induced internalization of Halo-CB1R significantly in 
these cells, but had no effect on the constitutive internalization of the receptor (Fig. 7C 
and D). These data indicate that the β-arr2 requirements of CB1R internalization are not 
specific to HeLa cells and are regulated similarly in Neuro-2a cells, which express 
endogenous CB1Rs. 
 
3.6. siRNA-mediated knock-down of clathrin heavy chain impairs both agonist-induced 
and constitutive internalization of CB1R 
 
Our results showed that constitutive CB1R internalization is independent of β-arr2 
binding, which raises the question whether this form of CB1R endocytosis is clathrin-
mediated. Therefore we applied siRNA-mediated knock-down of clathrin heavy chain in 
HeLa cells, and monitored constitutive endocytosis of Halo-CB1R under these conditions, 
as described above. Western blot analysis showed approximately 50% reduction in 
clathrin heavy chain levels of these cells (Suppl. Fig. 2B). We found that in cells 
transfected with clathrin heavy chain siRNA the spontaneous endocytosis of Halo-CB1R 
over 6 hours was significantly impaired compared to control siRNA-transfected cells 
(Fig. 8A). In the same experiments, agonist-induced CB1R internalization was also 
  21 
inhibited in clathrin heavy chain siRNA-transfected cells (Fig. 8B). These results show 
that, although the β-arr2 requirements for agonist-induced and constitutive CB1R 
internalization are different, both of them occur at least partly by a clathrin-mediated 
process. 
 
4. Discussion 
Our data show that, based on its β-arrestin binding characteristics, CB1R can be 
classified as a class A GPCR. The relatively low affinity of the binding between CB1R 
and β-arr2 is indicated by the low steepness of slope of the BRET saturation curve 
between the two molecules upon CB1R stimulation, and by the lack of detectable β-
arrestin2 in late endosomes after CB1R internalization in confocal experiments. 
Furthermore, we found in our BRET and confocal measurements that β-arr1 recruitment 
to the activated CB1R is essentially absent. This was not caused by the presence of the 
fluorescent tag on the C-terminus of CB1R because the binding of β-arr2 could be 
detected using the same receptor construct. The C-terminal tagging of β-arr1 is also not 
likely to cause the lack of the signal, as both β-arr1-Rluc and β-arr1-GFP constructs could 
be successfully used to detect β-arr1 recruitment to AT1R and β2AR. In a previous study, 
Bakshi et al. have shown using nuclear magnetic resonance (NMR) that a C-terminal 
fragment of CB1R is able to bind β-arr1 (Bakshi et al., 2007). Our data suggest that such 
binding between the two molecules, even if present, must be very weak compared to β-
arr2, when tested with native proteins in living cells.  
According to Oakley and colleagues, the class A or class B behavior of a GPCR is 
basically determined  by the absence or presence (respectively) of multiple 
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serine/threonine-containing clusters at the receptor C-terminus (Oakley et al., 2001). Our 
findings demonstrating a class A pattern for CB1R are in good agreement with this 
theory, as the C-terminus of CB1R contains only one such cluster (463-SVSTDTS-469) 
(Oakley et al., 2001). 
The class A behavior of CB1R may have an important impact on the pattern of 
receptor internalization, de- and resensitization. Furthermore, one should be aware of this 
property of CB1R when studying the signal transduction of the receptor. As mentioned in 
the introduction, β-arrestin can by itself moderate different intracellular signaling 
pathways. It was also shown that the localization of β-arrestin-dependent MAPK 
activation is dependent on the class A/class B characteristics of the involved receptor. 
After stimulation of class B receptors, β-arrestin activates a MAPK pool that remains 
associated with endosomes, whereas in the case of class A GPCRs, the MAPK activated 
by β-arrestin is able to reach the nucleus (Tohgo et al., 2003). CB1R is also known to 
mediate ERK phosphorylation, and early gene expression changes are associated with 
this pathway (Derkinderen et al., 2003; Graham et al., 2006; Valjent et al., 2001). 
However, G protein-dependent and β-arrestin-dependent MAPK activation of GPCRs are 
known to be spatially and temporally different (Ahn et al., 2004). Although the role of β-
arrestin molecules in CB1R-mediated ERK activation has been suggested (Daigle et al., 
2008a), the exact role of this process in CB1R-mediated ERK activation requires 
additional studies. It is very likely that the class A behavior of CB1R is associated with a 
characteristic distribution of MAPK activation, nevertheless, direct studies that address 
these questions are needed to confirm them. 
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Agonist-induced internalization of G protein-coupled receptors is usually the 
direct consequence of receptor activation. Similarly, constitutive receptor internalization 
is also generally considered to be a result of constitutive receptor activity. This scenario 
also implies that the mechanisms that control the endocytosis of a given receptor after 
agonist activation are similarly engaged in its spontaneous endocytosis. This has also 
been the prevailing idea in the case of CB1R trafficking. In our study, the Halo labeling 
technique was utilized to analyze the mechanism of internalization of CB1R. The cellular 
trafficking of GPCRs is often followed by the use of fluorescent proteins fused mainly to 
the C-terminus of the receptor. However, the detailed analysis of the internalization of 
such receptor variants under microscope is often hindered by the continuously visible 
intracellular receptor populations (representing either maturing or endosomal receptors), 
and this is especially true for constitutively internalizing receptors, such as CB1R. 
Receptor distribution on cell surface and in intracellular vesicles is a function of 
internalization and recycling rates, representing an actual equilibrium of these processes. 
When cells are treated with a receptor antagonist, theoretically both processes can be 
altered. Receptor internalization can be inhibited by decreasing constitutive activity, or 
recycling may be altered by targeting the receptor to different intracellular trafficking 
routes. Thus, measuring C-terminally tagged receptor distribution in cells can be 
misleading when trafficking of constitutively internalizing receptors is measured. 
Furthermore, alterations in the trafficking of C-terminally tagged CB1R have been also 
suggested (Rozenfeld, 2011). All these difficulties can be overcome by the use of N-
terminal tags that can be covalently labeled with small, membrane-impermeable 
fluorescent ligands. Indeed, such receptor variants (i.e. SNAP and CLIP-tagged 
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receptors) have been utilized in the studying of CB1R internalization (Ward et al., 2011a, 
2011b). Here we used another variant, the HaloTag labeled form of CB1R. As indicated 
in our study, G protein activation and β-arrestin binding of Halo-CB1R have not been 
altered due to the N-terminal labeling, and therefore this receptor can be used to study 
receptor trafficking with the same advantages as the above mentioned ones. 
The main finding of our study is that constitutive CB1R internalization is not only 
independent of the active/inactive state of the receptor, but it occurs via a mechanism 
which is at least partly different from activity-driven endocytosis.  
This finding is based on our observations that agonist-induced CB1R 
internalization requires β-arr2 binding, whereas constitutive internalization of the 
receptor does not. As described in the introduction, the binding between β-arr2 and CB1R 
as well as a role for β-arrestins in the desensitization of CB1R have been demonstrated by 
former studies (Bakshi et al., 2007; Daigle et al., 2008a, 2008b; Jin et al., 1999; 
Kouznetsova et al., 2002; Nguyen et al., 2012; Singh et al., 2011). Therefore, the role of 
β-arr2 in CB1R endocytosis may seem to be a logical consequence of its recruitment to 
the receptor. However, in fact, none of these studies provided direct evidence at the 
cellular level that β-arrestin binding is required for CB1R internalization. This is 
important because various examples demonstrate that β-arrestin2 recruitment and 
receptor internalization can be independent processes, as it is the case e.g. with the PAR1 
thrombin receptor (Paing et al., 2002), the CXCR2 chemokine receptor (Fan et al., 2001; 
Zhao et al., 2004), the N-formyl peptide receptor (FPR) (Vines et al., 2003), or at high 
agonist concentration the AT1 angiotensin receptor (Gaborik et al., 2001; Hunyady and 
Catt, 2006; Zhang et al., 1996). Therefore, it is important to study directly the β-arrestin 
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dependence of CB1R internalization. In the present study we performed these 
experiments using a dominant-negative β-arrestin2 mutant and siRNA-mediated knock-
down of β-arr2. Our data demonstrate that β-arr2 binding is required for the agonist-
induced internalization of CB1R.  
In contrast, using similar approaches, we have demonstrated in our study that, 
although both agonist-induced and constitutive CB1R endocytosis are mediated at least 
partly by clathrin, constitutive internalization of CB1R is a β-arr2-independent process. 
Earlier, McDonald et al. raised the idea that these two forms of CB1R internalization may 
occur via different, or at least partly different, pathways (McDonald et al., 2007a). Our 
work provides experimental evidence to support their proposal. Such regulatory 
phenomenon is however not a unique property of CB1R, as similar differences in the 
mechanisms of tonic versus agonist-induced internalization have been demonstrated in 
the case of other GPCRs, such as the TP thromboxane A2 receptor (Parent et al., 2001), 
the Y1 neuropeptide Y receptor (Holliday et al., 2005) or the mGlu1 metabotropic 
glutamate receptor (Dale et al., 2001). Furthermore, we also show here that the 
spontaneous internalization of CB1R is not simply a consequence of its constitutive 
activity, since it also occurs in the presence of the CB1R inverse agonist AM251, i.e. 
when the receptors are stabilized in their inactive state. This is in line with the data 
published by McDonald et al., which showed no alterations in the cellular distribution of 
CB1R upon inverse agonist treatment in neurons (McDonald et al., 2007a). In contrast, a 
previous study using inverse agonist treatment (Leterrier et al., 2006), and our study 
using DAGL-inhibitor treatment (Turu et al., 2007) have shown an inhibition of basal 
endocytosis of the receptor upon these treatments, suggesting a role for basal CB1R 
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activity in this process. Since active receptors internalize by β-arr2-dependent 
mechanism, those results may seem to be contradictory with our present results, where 
we now find that interfering with β-arr2 expression or function does not have effect on 
constitutive endocytosis. One explanation for these differences is our previous 
observation that CB1R has different basal activity in different cell types used in these 
studies (data not shown). The other possibility is that inhibition of receptor activity may 
interfere with intracellular trafficking, so it might also accelerate recycling, thus the rate 
of activity-dependent constitutive internalization may be well overestimated in those 
experiments. This is supported by the observation, that in resting cells, β-arr2 is not 
translocated to the plasma membrane, suggesting a low percent of active receptors there 
(Fig. 2E). The advantage of using the Halo technique is that we can now selectively 
follow trafficking of surface receptors, thus recycling becomes less of an issue. 
Therefore, combined with previous results, the data presented here are consistent with a 
model in which continuous CB1R internalization in resting cells is caused to a certain 
extent by basal release of endocannabinoids, the rate of which may vary in different cell 
types, while another part of basal CB1R internalization is ‘truly’ constitutive, i.e. it is 
independent of CB1R activation and requires a mechanism that is different from agonist-
induced, β-arrestin2-dependent internalization. 
Recent work by Kleyer and colleagues demonstrated that in immune cells 
expressing endogenous CB1Rs, internalization of the receptor is independent of its 
activation (Kleyer et al., 2012), suggesting that agonist-dependent internalization may not 
have physiological role in primary cells. However, in hippocampal neurons, it has been 
demonstrated that agonist treatment leads to internalization (Coutts et al., 2001). These 
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data, together with differences detected in the regulation of constitutive internalization 
(Leterrier et al., 2006; McDonalds et al., 2007a) are in good agreement with our results 
showing that CB1R internalizes through at least two different mechanisms. Depending on 
the environment in a particular cell type, or on the methods used by different groups, one 
or the other mechanism might be more prevalent. 
 The physiological role of spontaneous CB1R endocytosis is not clear at the 
moment. It has been suggested that constitutive CB1R internalization in neurons have a 
role in the axonal distribution of the receptor (Leterrier et al., 2006; McDonald et al., 
2007a). This underlines the importance of constitutive CB1R endocytosis in the central 
nervous system. However, CB1Rs are also expressed in peripheral cannabinoid target 
tissues, and we have practically no data what is the importance of such trafficking feature 
of the receptor in these cells. On the other hand, maintained functionality of intracellular 
CB1R populations has been demonstrated (Brailoiu et al., 2011; Rozenfeld and Devi, 
2008), and this raises the idea that the activation of intracellular versus plasma membrane 
CB1R populations may differentially regulate cell functions (Rozenfeld, 2011). 
Nevertheless, additional studies are needed to further clarify the importance of 
constitutive CB1R endocytosis in different body tissues. 
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Figure legends 
 
Fig.1 BRET measurements showing the recruitment of β-arr1 and β-arr2 to CB1R, 
AT1R and β2AR upon agonist stimulus 
A, CB1R-mVenus was co-expressed with β-arr1-Rluc or β-arr2-Rluc in HeLa cells, and 
BRET was measured upon WIN55 (10 μM) stimulus. Measurements were baseline-
corrected to vehicle curves (indicated by horizontal dashed line). Arrow indicates the 
time point of stimulation. Data are mean±SEM. B-D, BRET titration curves showing the 
relative affinities of AT1R (B), β2AR (C) and CB1R (D) to β-arrestin isoforms. HeLa cells 
were transfected with constant amounts of β-arr1-Rluc or β-arr2-Rluc, and varying 
amounts of the mVenus-tagged receptor, yielding different acceptor/donor ratios. 
Average BRET change between 3 to 5 minutes after agonist stimulus (100 nM 
angiotensin II (B), 1 μM isoproterenol (C) or 10 μM WIN55 (D)) was plotted against 
mVenus/Rluc intensity ratios measured at the beginning of each experiment. Data 
resulting from at least 3 independent experiments were fitted using non-linear regression 
with a one-site binding equation. 
 
Fig.2 Confocal microscopy analysis indicates class A β-arrestin binding pattern of 
CB1R 
β-arr1-GFP (A-D) or β-arr2-GFP (E-H) and CB1R-mCherry were co-expressed in HeLa 
cells and analyzed by confocal microscopy. Under control conditions, β-arr1-GFP shows 
diffuse cytoplasmic and nuclear localization (A). After 20 minutes of WIN55 (10 μM) 
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stimulus, no change in β-arr1-GFP distribution can be detected (C). β-arr2-GFP shows 
diffuse cytoplasmic localization in control cells (E, inset). After 20 minutes of WIN55 
(10 μM) stimulus, β-arr2-GFP can be detected in punctuate structures, however only in 
the close proximity of the plasma membrane (G, inset, arrows indicate β-arr2-GFP 
puncta). A large proportion of CB1R is constitutively intracellular, reflecting to 
spontaneous endocytosis of the receptor (B,D,F,H). Images are representative from 3 
independent experiments. Scale bar 10 μm. 
 
Fig.3 Agonist-induced internalization of CB1R is impaired by dominant-negative β-
arr2 
Halo-CB1R was expressed in HeLa cells alone (A,B,C) or together with wild-type β-arr2-
RFP (D-G) or β-arr2-V54D-RFP (H-K), and analyzed with confocal microscopy after 15 
min Halo-Alexa488 staining and 30 min vehicle (A,D,E,H,I) WIN55 (10 μM, B,F,G,J,K) 
or WIN55+AM251 (10 μM+30 μM, respectively, C) treatment. Vehicle treatment causes 
no substantial Halo-CB1R internalization (A,D,H) in either cell population, whereas 
WIN55 treatment leads to massive endocytosis of the receptor in control (B) or β-arr2-
RFP- (F,G), but not in β-arr2-V54D-RFP- (J,K) expressing cells. WIN55-induced 
internalization is blocked by co-treatment with AM251 (C). Images are representative 
from 3 independent experiments. Scale bar 10 μm. 
 
Fig.4 Agonist-induced internalization of CB1R is impaired by β-arr2-specific siRNA 
A, Western blot analysis shows an approximately 50% reduction in the β-arr2 protein 
levels of β-arr2 siRNA-transfected cells compared to control siRNA-transfected cells. 
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n=3 B-E, HeLa cells were transfected with Halo-CB1R and control (B,D) or β-arr2-
specific (C,E) siRNA, and analyzed with confocal microscopy after 15 min Halo-
Alexa488 staining and 30 min vehicle (B,C) or WIN55 (10 μM, D,E) treatment. Vehicle 
treatment causes no substantial Halo-CB1R internalization in either cell population (B,C), 
whereas WIN55 treatment leads to massive endocytosis of the receptor in control (D), but 
not in β-arr2 (E) siRNA-transfected cells. Scale bar 10 μm. F, Quantification of the data 
using an intracellular to total cell fluorescence ratio shows a significant increase in 
intracellular receptor number upon WIN55 stimulus in control siRNA-transfected cells, 
and this is significantly reduced in cells transfected with β-arr2 siRNA. Data are 
mean+SEM, n=6, *p<0.05, ns - not significant. 
 
Fig.5 BRET measurements showing the β-arr2 dependence of agonist-induced CB1R 
internalization 
CB1R-Sluc was co-expressed with ICAM-YFP in HeLa cells, and BRET was measured to 
follow the agonist-induced removal of the receptor from the plasma membrane. A, BRET 
signal decrease upon WIN55 (10 μM) stimulus can be detected in cells co-transfected 
with pcDNA3.1 (open circles). Co-expression of wild-type β-arr2 has no significant 
impact on BRET change (closed triangles). Co-expression of β-arr2-V54D substantially 
reduces BRET signal decrease (open triangles). Data are all mean±SEM, n=8. B, BRET 
signal decrease upon WIN55 (10 μM) stimulus can be detected in control siRNA-
transfected cells (closed triangles). The BRET signal decrease is substantially reduced in 
cells transfected with β-arr2 siRNA (open triangles). Data are all mean±SEM, n=4. 
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Measurements were baseline-corrected to vehicle curves (indicated by horizontal dashed 
lines). Arrows indicate the time point of stimulation. 
 
Fig.6 Constitutive internalization of CB1R is not affected by inverse agonist 
treatment or dominant-negative β-arr2 
Halo-CB1R was expressed in HeLa cells alone (A,B,C) or together with wild-type β-arr2-
RFP (D,E) or β-arr2-V54D-RFP (F,G), and analyzed by confocal microscopy after 15 
min Halo-Alexa488 staining and  5 h 45 min incubation at 37°C, 5% CO2. In control cells 
(A), a substantial amount of Halo-CB1R can be detected intracellularly. Internalization is 
enhanced in the presence of WIN55 (10 μM, B) but not affected by AM251 (30 μM, C). 
Constitutive internalization of the receptor can be detected in cells expressing wild-type 
β-arr2-RFP (D,E) and also in cells expressing β-arr2-V54D-RFP (F,G, see cell indicated 
with arrow). Images are representative from 3 independent experiments. Scale bar 10 μm. 
 
Fig.7 Constitutive internalization of CB1R is not affected by β-arr2-specific siRNA 
A and C, HeLa (A) or Neuro-2a (C) cells were transfected with Halo-CB1R and control 
or β-arr2-specific siRNA, and analyzed with confocal microscopy after 15 min Halo-
Alexa488 staining and 5 h 45 min incubation at 37°C, 5% CO2. In both control and β-arr2 
siRNA-transfected cells, substantial amounts of intracellular receptors can be detected. 
Quantification of the data using an intracellular to total cell fluorescence ratio shows no 
significant difference between control or β-arr2 siRNA-transfected cells after the 6 hours 
of incubation. B and D, In the same experiments, control or β-arr2 siRNA-transfected 
HeLa (B) or Neuro-2a (D) cells were incubated at 37°C, 5% CO2 for 5 h 15 min followed 
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by 15 min Halo-Alexa488 staining and 30 min WIN55 (10 μM) treatment. A substantial 
amount of internalized receptors was detected in control, but not in β-arr2 siRNA-
transfected cells. Data quantification shows that internalization upon WIN55 stimulus 
after 5 h 30 min is significantly reduced in β-arr2 siRNA-transfected cells. Scale bar 10 
μm. Data are mean+SEM, n=3, *p<0.05. 
 
Fig.8 Constitutive internalization of CB1R is impaired by clathrin heavy chain-
specific siRNA 
A, HeLa cells were transfected with Halo-CB1R and control or clathrin heavy chain-
specific siRNA (clathrin siRNA), and analyzed with confocal microscopy after 15 min 
Halo-Alexa488 staining and 5 h 45 min incubation at 37°C, 5% CO2. A substantial 
amount of internalized receptors was detected in control, but not in clathrin siRNA-
transfected cells. Quantification of the data using an intracellular to total cell fluorescence 
ratio shows significant difference between control or clathrin siRNA-transfected cells 
after the 6 hours of incubation. B, In the same experiments, control or clathrin siRNA- 
transfected HeLa cells were incubated at 37°C, 5% CO2 for 5 h 15 min followed by 15 
min Halo-Alexa488 staining and 30 min WIN55 (10 μM) treatment. A substantial amount 
of internalized receptors was detected in control, but not in β-arr2 siRNA-transfected 
cells. Data quantification shows that internalization upon WIN55 stimulus after 5 h 30 
min is significantly reduced in clathrin siRNA-transfected cells. Scale bar 10 μm. Data 
are mean+SEM, n=3, *p<0.05. 
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Suppl. Fig.1 Confocal microscopy analysis showing the β-arrestin binding of AT1R 
and β2AR 
AT1R-mCherry (A-D) or β2AR-Cerulean (E-H) were co-expressed with β-arr1-GFP 
(A,B,E,F) or β-arr2-GFP (C,D,G,H) in HeLa cells and analyzed by confocal microscopy.  
In AT1R-mCherry expressing cells, both β-arr1-GFP and β-arr2-GFP could be detected in 
intracellular vesicles after 20 minutes of angiotensin II (Ang II, 100 nM) stimulus (A,C). 
In β2AR-Cerulean expressing cells, β-arr1-GFP and β-arr2-GFP could be detected in 
puncta at the plasma membrane but not in intracellular vesicles after 20 minutes of 
isoproterenol (ISO, 1 μM) stimulus (E,G). Images are representative from 3 independent 
experiments. Scale bar 10 μm 
 
Suppl. Fig.2 Western blot images showing siRNA induced protein knock-down 
Neuro-2a (A) or HeLa (B) were transfected with Halo-CB1R and control or mouse β-
arrestin2-specific (A) or clathrin heavy chain specific (B) siRNA (clathrin siRNA) as 
described in Chapter 2.3. Western blot experiments were carried out as described in 
Chapter 2.7. A, Data quantification shows an approximately 80% reduction in the β-arr2 
protein levels of β-arr2 siRNA-transfected Neuro-2a cells compared to control siRNA-
transfected cells. B, Data quantification shows an approximately 50% reduction in the 
clathrin heavy chain (clathrin HC) protein levels of clathrin siRNA-transfected HeLa 
cells compared to control siRNA-transfected cells. Data are mean+SEM, n=3 
 
 
 
 CB1R binds β-arrestin2 but not β-arrestin1 upon activation. 
 Agonist-induced internalization of CB1R is β-arrestin2 dependent. 
 Constitutive CB1R internalization does not require β-arrestin2. 
 Agonist-induced and constitutive CB1R endocytosis are distinctly regulated 
processes. 
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